Special use results survey for interstitial lung disease of ENHERTU FOR INTRAVENOUS DRIP INFUSION 100mg-gastric cancer-

Special use results survey for interstitial lung disease of ENHERTU FOR INTRAVENOUS DRIP INFUSION 100mg in unresectable advanced or recurrent gastric cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2001200001

Enrollment

900

Registered

2020-10-13

Start date

2020-09-25

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable advanced / recurrent gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with unresectable advanced / recurrent gastric cancer who start administration of this drug within the enrollment period

Exclusion criteria

Exclusion criteria: NONE

Design outcomes

Primary

Measure	Time frame
Drug-related ILD adjudicated in an independent ILD adjudication committee	—

Contacts

Public ContactGPSP Contact

DAIICHI SANKYO Co.,Ltd.

contact_gpsp_jp@daiichisankyo.com+81-3-6225-1059

Outcome results